← All drugs
Drug · FAERS side-effect profile with label screen

Leuprolide Acetate side effects: what 77,109 FDA adverse event reports show

Leuprolide Acetate · Camcevi · 1,206 reaction terms · 208,964 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Gonadotropin-releasing hormone (gnrh) agonist

FDA label, Indications wording

Brand names

Camcevi

openFDA label

Who reports

77,109 reports · 46% serious · 12,049 with death outcome · 23% female

openFDA FAERS counts, all years, deduplication not applied

Used for

CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.

FDA label, Indications and Usage

What it is

CAMCEVI is a sterile formulation of leuprolide mesylate for subcutaneous injection. CAMCEVI is designed to deliver approximately 42 mg of leuprolide over 6 months. Leuprolide mesylate is a synthetic nonapeptide analog of naturally occurring GnRH and is a GnRH agonist.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 4Likely indication confounding 2Reporting / coding artifact 9Lab value / disease marker 8Not in label — unassessed 16
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,166 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Intercepted product preparation error9,222881.5
845.5–919.0ROR 1,001.1 · calibrated p 2e-17 ✓
205.8 EB05 202.3 · IC025 +7.6
3/3 methods agree
Not in label — unassessedserious n=41 · 97% cliniciannot reported in cached trials
Bulbospinal muscular atrophy congenital21267.4
146.0–489.5ROR 267.4 · calibrated p 9e-10 ✓
119.8 EB05 82.7 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=20 · ♀ 0% (drug 23%) · 100% cliniciannot reported in cached trials
Syringe issue7,900224.8
218.3–231.4ROR 250.3 · calibrated p 5e-11 ✓
122.5 EB05 120.3 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=64 · 93% cliniciannot reported in cached trials
Prostatic specific antigen abnormal447204.3
180.7–231.0ROR 205.5 · calibrated p 4e-10 ✓
115.7 EB05 106.9 · IC025 +6.5
3/3 methods agree
Lab value / disease markerserious n=222 · ♀ 0% (drug 23%)NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE)
Abscess sterile55173.0
123.2–242.8ROR 173.1 · calibrated p 4e-9 ✓
101.8 EB05 81.1 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=15 · ♀ 100% (drug 23%) · 100% cliniciannot reported in cached trials
Blood luteinising hormone abnormal20172.5
98.3–302.6ROR 172.5 · calibrated p 2e-8 ✓
95.9 EB05 65.5 · IC025 +4.1
3/3 methods agree
Lab value / disease marker–not reported in cached trials
Blood testosterone abnormal385143.4
126.7–162.2ROR 144.1 · calibrated p 7e-9 ✓
93.2 EB05 85.7 · IC025 +6.2
3/3 methods agree
Lab value / disease markerserious n=173 · ♀ 0% (drug 23%)not reported in cached trials
Intercepted medication error1,13186.7
81.1–92.7ROR 88.0 · calibrated p 3e-7 ✓
65.7 EB05 62.5 · IC025 +5.9
3/3 methods agree
Not in label — unassessed–not reported in cached trials
Blood testosterone increased42967.5
60.7–75.0ROR 67.8 · calibrated p 2e-6 ✓
54.0 EB05 49.8 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious n=207 · ♀ 0% (drug 23%)not reported in cached trials
Prostatic specific antigen increased2,42157.5
55.1–60.1ROR 59.4 · calibrated p 4e-6 ✓
47.5 EB05 45.9 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious PRR 66.5 · ♀ 0% (drug 23%)NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE)
Product physical consistency issue95157.2
53.3–61.3ROR 57.9 · calibrated p 5e-6 ✓
47.2 EB05 44.8 · IC025 +5.4
3/3 methods agree
Reporting / coding artifact94% cliniciannot reported in cached trials
Radiation proctitis3153.8
36.6–79.2ROR 53.8 · calibrated p 2e-5 ✓
43.8 EB05 32.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=27 · ♀ 0% (drug 23%)not reported in cached trials
Endometriosis77252.4
48.6–56.6ROR 53.0 · calibrated p 1e-5 ✓
44.0 EB05 41.4 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=519 · ♀ 100% (drug 23%) · 75% consumernot reported in cached trials
Laparoscopy4152.0
37.2–72.6ROR 52.0 · calibrated p 2e-5 ✓
42.9 EB05 32.9 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=40 · ♀ 100% (drug 23%) · 100% consumernot reported in cached trials
Child abuse3848.6
34.4–68.7ROR 48.6 · calibrated p 3e-5 ✓
40.5 EB05 30.8 · IC025 +4.2
3/3 methods agree
Reporting / coding artifactserious n=38 · ♀ 0% (drug 23%) · 100% cliniciannot reported in cached trials
Device leakage6,23046.9
45.7–48.1ROR 50.9 · calibrated p 1e-5 ✓
40.0 EB05 39.2 · IC025 +5.3
3/3 methods agree
Reporting / coding artifactserious n=40 · 97% cliniciannot reported in cached trials
Hormone-refractory prostate cancer17146.3
39.4–54.5ROR 46.4 · calibrated p 2e-5 ✓
39.5 EB05 34.7 · IC025 +4.9
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=170 · ♀ 0% (drug 23%)not reported in cached trials
Prostate cancer recurrent8946.0
36.8–57.6ROR 46.1 · calibrated p 3e-5 ✓
39.1 EB05 32.8 · IC025 +4.7
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=89 · ♀ 0% (drug 23%)not reported in cached trials
Cystitis radiation2744.3
29.5–66.5ROR 44.3 · calibrated p 6e-5 ✓
37.2 EB05 26.9 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=26 · ♀ 0% (drug 23%)not reported in cached trials
Product reconstitution quality issue12043.8
36.1–53.1ROR 43.8 · calibrated p 4e-5 ✓
37.5 EB05 32.2 · IC025 +4.7
3/3 methods agree
Reporting / coding artifact♀ 0% (drug 23%)not reported in cached trials
Victim of child abuse3443.3
30.1–62.2ROR 43.3 · calibrated p 6e-5 ✓
36.7 EB05 27.5 · IC025 +4.0
3/3 methods agree
Reporting / coding artifactserious n=34 · ♀ 0% (drug 23%) · 100% cliniciannot reported in cached trials
Epidural lipomatosis4742.3
31.1–57.5ROR 42.3 · calibrated p 6e-5 ✓
36.2 EB05 28.3 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=47 · ♀ 0% (drug 23%) · 100% cliniciannot reported in cached trials
Hot flush (hot flashes)9,56439.4
38.7–40.2ROR 44.9 · calibrated p 3e-5 ✓
34.5 EB05 33.9 · IC025 +5.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 28.1 · 84% consumerNCT01081873: 2/2,714 (0.1%) on Leuprolide
Palliative care19138.7
33.2–45.0ROR 38.7 · calibrated p 7e-5 ✓
33.8 EB05 30.0 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=191 · ♀ 0% (drug 23%)not reported in cached trials
Prostatic specific antigen decreased4738.3
28.2–52.0ROR 38.3 · calibrated p 1e-4 ✓
33.2 EB05 26.0 · IC025 +4.2
3/3 methods agree
Lab value / disease markerserious n=26 · ♀ 0% (drug 23%) · 100% consumerNCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE)
Product administered by wrong person4335.9
26.1–49.4ROR 35.9 · calibrated p 1e-4 ✓
31.4 EB05 24.3 · IC025 +4.0
3/3 methods agree
Reporting / coding artifact–not reported in cached trials
Blood luteinising hormone increased2834.7
23.4–51.4ROR 34.7 · calibrated p 2e-4 ✓
30.2 EB05 21.9 · IC025 +3.7
3/3 methods agree
Lab value / disease marker♀ 100% (drug 23%) · 100% cliniciannot reported in cached trials
Oestradiol increased2929.1
19.9–42.8ROR 29.2 · calibrated p 5e-4 ✓
26.0 EB05 19.0 · IC025 +3.6
3/3 methods agree
Lab value / disease marker♀ 100% (drug 23%) · 100% cliniciannot reported in cached trials
Post procedural diarrhoea4928.9
21.5–38.8ROR 28.9 · calibrated p 4e-4 ✓
26.0 EB05 20.4 · IC025 +3.9
3/3 methods agree
Reporting / coding artifactserious n=15 · ♀ 0% (drug 23%) · 73% consumernot reported in cached trials
Terminal state64128.7
26.4–31.1ROR 28.9 · calibrated p 3e-4 ✓
26.0 EB05 24.3 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=639 · ♀ 0% (drug 23%) · 75% consumerNCT01081873: 2/2,714 (0.1%) on Leuprolide (serious AE)
Testicular atrophy7625.9
20.5–32.8ROR 26.0 · calibrated p 7e-4 ✓
23.6 EB05 19.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=29 · ♀ 0% (drug 23%) · 82% consumernot reported in cached trials
Adnexa uteri pain10323.8
19.5–29.1ROR 23.8 · calibrated p 1e-3 ✓
21.9 EB05 18.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=31 · ♀ 100% (drug 23%) · 83% consumernot reported in cached trials
Metastases to bladder2222.7
14.7–35.1ROR 22.7 · calibrated p 0.002 ✓
20.6 EB05 14.3 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=22 · ♀ 0% (drug 23%)NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE)
Menstruation normal2422.0
14.5–33.4ROR 22.1 · calibrated p 0.002 ✓
20.1 EB05 14.1 · IC025 +3.2
3/3 methods agree
Reporting / coding artifact♀ 100% (drug 23%) · 100% consumernot reported in cached trials
Lipid metabolism disorder2722.0
14.9–32.6ROR 22.0 · calibrated p 0.002 ✓
20.1 EB05 14.5 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=24 · ♀ 0% (drug 23%) · 100% cliniciannot reported in cached trials
Device connection issue15321.8
18.5–25.7ROR 21.9 · calibrated p 0.001 ✓
20.2 EB05 17.7 · IC025 +4.0
3/3 methods agree
Reporting / coding artifact♀ 0% (drug 23%) · 100% cliniciannot reported in cached trials

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Leuprolide as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (7 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Hot flush (hot flashes)9,56439.4
38.7–40.2ROR 44.9 · calibrated p 3e-5 ✓
34.5 EB05 33.9 · IC025 +5.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 28.1 · 84% consumerNCT01081873: 2/2,714 (0.1%) on Leuprolide
Intercepted product preparation error9,222881.5
845.5–919.0ROR 1,001.1 · calibrated p 2e-17 ✓
205.8 EB05 202.3 · IC025 +7.6
3/3 methods agree
Not in label — unassessedserious n=41 · 97% cliniciannot reported in cached trials
Death8,5282.7
2.7–2.8ROR 2.9 · calibrated p 0.652
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Outcome field, not a reactionserious PRR 3.4 · ♀ 1% (drug 23%)NCT01081873: 8/2,714 (0.3%) on Leuprolide (serious AE)
Syringe issue7,900224.8
218.3–231.4ROR 250.3 · calibrated p 5e-11 ✓
122.5 EB05 120.3 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=64 · 93% cliniciannot reported in cached trials
Device leakage6,23046.9
45.7–48.1ROR 50.9 · calibrated p 1e-5 ✓
40.0 EB05 39.2 · IC025 +5.3
3/3 methods agree
Reporting / coding artifactserious n=40 · 97% cliniciannot reported in cached trials
Wrong technique in product usage process5,4617.5
7.3–7.7ROR 8.0 · calibrated p 0.066
7.3 EB05 7.2 · IC025 +2.8
3/3 methods agree
Reporting / coding artifactserious PRR 0.7not reported in cached trials
Fatigue (tiredness)5,0981.8
1.7–1.8ROR 1.8 · calibrated p 0.857
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
serious PRR 1.9 · 77% consumerNCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE)
Injection site pain (pain where injected)4,8704.4
4.3–4.5ROR 4.6 · calibrated p 0.276
4.4 EB05 4.3 · IC025 +2.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 6.9 · 85% consumernot reported in cached trials
Prostatic specific antigen increased2,42157.5
55.1–60.1ROR 59.4 · calibrated p 4e-6 ✓
47.5 EB05 45.9 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious PRR 66.5 · ♀ 0% (drug 23%)NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE)
Asthenia (weakness)2,4061.7
1.7–1.8ROR 1.8 · calibrated p 0.811
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
serious PRR 2.0 · 70% consumernot reported in cached trials
Off label use (used outside approved label)2,3500.7
0.7–0.8ROR 0.7 · calibrated p 0.144
0.7 EB05 0.7 · IC025 -0.5
PRR-only: not supported by EBGM or IC
Reporting / coding artifactserious PRR 0.6 · ♀ 61% (drug 23%)not reported in cached trials
Drug ineffective (drug did not work)2,2800.5
0.5–0.5ROR 0.5 · calibrated p 0.035 ✓
0.5 EB05 0.5 · IC025 -1.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifactserious PRR 0.8not reported in cached trials
Fall1,9941.6
1.6–1.7ROR 1.7 · calibrated p 0.739
1.6 EB05 1.6 · IC025 +0.6Not in label — unassessedserious PRR 2.2not reported in cached trials
Arthralgia (joint pain)1,9641.3
1.2–1.3ROR 1.3 · calibrated p 0.507
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
serious PRR 1.3 · 71% consumernot reported in cached trials
Pain1,9350.9
0.8–0.9ROR 0.9 · calibrated p 0.213
0.9 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Labeled adverse reaction
exact term
serious PRR 1.0 · ♀ 47% (drug 23%)not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Medroxyprogesterone acetate ↔ Meningioma.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Leuprolide?

In FDA FAERS, the most frequently co-reported reaction terms for Leuprolide are hot flush, intercepted product preparation error, syringe issue, fatigue, injection site pain, prostatic specific antigen increased. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Leuprolide have an FDA boxed warning?

No. The FDA label retrieved for Leuprolide has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Leuprolide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.